In addition, EBV− cHL patients carrying the HLA-DRB1*15/16 (DR2) risk allele more frequently retained HLA class II expression than non-carriers and EBV+ cHL patients carrying the HLA-B*37 risk allele more frequently retained HLA expression compared to non-carriers. This evidence concerns the gene HLA-B and classic Hodgkin lymphoma.